Neuropathic Pain - NSL-043 Achieves Phase I Trial Success
NeuroDiscovery Ltd (ASX: NDL), a specialty neuroscience services provider and drug development company, is pleased to announce the success of its Phase I clinical trial of NSL-043. This trial is the first of two Phase I trials, designed to test the safety and tolerability of an oral formulation of NSL-043. The second trial is ongoing, and both are being undertaken in collaboration with the Company’s 50/50 partner, Sosei Group Corporation.
More: continued here